Condition: Small Cell Lung Cancer · Sponsor: Akeso
This is a randomized, double-blind, phase III clinical study to compare the efficacy and safety of AK112 to placebo as consolidation treatment for patients with limited stage small cell lung cancer who have not progressed following concurrent chemoradiation therapy.
This description comes directly from the study's public registry record.
Zhifang Yao, M.D. · +86-0760-89873999 · clinicaltrials@akesobio.com
Always discuss trial participation with your own doctor first.
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | Recruiting |
| The First Medical Center of Chinese PLA General Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Beijing Chest Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Beijing Luhe Hospital, Capital Medical University | Beijing, Beijing Municipality, China | Recruiting |
| Cancer Hospital, Chinese Academy of Medical Sciences | Beijin, Beijin, China | Recruiting |
| The First Affiliated Hospital of Chongqing Medical University | Chongqing, Chongqing Municipality, China | Recruiting |
| Fujian Cancer Hospital | Fuzhou, Fujian, China | Recruiting |
| PLA No. 900 Hospital of the Joint Support Force | Fuzhou, Fujian, China | Recruiting |
| Longyan First Hospital | Longyan, Fujian, China | Recruiting |
| Zhangzhou Municipal Hospital of Fujian Province | Zhangzhou, Fujian, China | Recruiting |
| Gansu Provincial Cancer Hospital | Lanzhou, Gansu, China | Recruiting |
| Jiangmen Central Hospital | Jiangmen, Guangdong, China | Recruiting |
+ 41 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07010263